The new acquisition offer from Royalty Pharma, announced Friday, included an upwardly revised bid of $13.00 a share (increased from a previous $12.50-per-share bid), plus contingent value rights (CVRs) worth as much as $2.50 a share, according to Elan.
But the Elan board says "the value gap between the underlying value of Elan plc and the totality of its business platform and the Royalty Pharma/Echo bid remains significant and the $13.00 cash and $2.50 CVR structure continues to be wholly inadequate for Elan shareholders."
In addition to the most recent offer from Royalty Pharma, Elan announced its board and financial advisors will review several "unsolicited corporate enquiries," in its effort to explore "all opportunities that maximize the full value of the company for its shareholders."
Fool contributor Tim Brugger has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.